Danimer Scientific breaks ground, new facility will create biodegradable material

Gov. Brian Kemp made a stop in Southwest Georgia for Danimer Scientific’s groundbreaking ceremony in Bainbridge. It’s a $700 million dollar expansion. The company is a leading developer and manufacturer of biodegradable materials. The new plant will be a 2,000,000-square-foot facility. Officials say it’s the largest plant that will make polyhydroxyalkanoate, a biodegradable plastic that…

Read More

Omicron has drug companies preparing for the worst. Here are their plans to counterattack the newest COVID-19 variant.

Drug companies are preparing for Omicron to be the next major challenge of the pandemic. The newest variant’s mutations could weaken vaccine protection, though that remains unknown. While much is still uncertain, the pharmaceutical industry is already planning its counterattack. Vaccine and drug developers are preparing for the Omicron variant to turn into the next…

Read More

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent

GeoVax Intellectual Property Portfolio Includes More than 70 Granted/Pending Patent Applications GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 16/068,527 entitled “Compositions and Methods for Generating an Immune…

Read More

Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio

Expands Alcon’s leading surgical portfolio and leverages the company’s commercial execution expertise Strong safety and efficacy profile evidenced by five-year study on Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device Indicated to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery*, Hydrus Microstent is part of a large surgical glaucoma market…

Read More

PFIZER AND BIONTECH RECEIVE EXPANDED U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER TO INCLUDE INDIVIDUALS 18 AND OLDER

Expanded authorization allows more Americans to receive a booster dose to help preserve a high-level of protection against COVID-19 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to…

Read More

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation…

Read More

Vizzia Technologies Releases Advanced Healthcare RTLS Software Platform

InVIEW℠ provides real-time data analytics and reports to improve patient care  Vizzia Technologies, a leading software and managed service provider of real-time location systems (RTLS) for healthcare organizations, has commercially released a significant upgrade to its InVIEW℠ software platform. Vizzia InVIEW℠ offers a faster, more secure, cloud-based experience, with industry-requested features, powerful analytics, and new maps. The…

Read More

AdvaMed Statement on The Repeal of MCIT

Today, the Advanced Medical Technology Association (AdvaMed) released the following statement from President and CEO Scott Whitaker regarding the Centers for Medicare and Medicaid Services (CMS) recission of the Medicare Coverage for Innovative Technologies (MCIT) final rule: “The MCIT rule was truly transformational for Medicare patients and doctors looking for life-saving and life-enhancing breakthrough medical…

Read More

GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine

Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients Complements GeoVax’s Pan-Coronavirus Vaccine Program GeoVax Labs Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has entered into an exclusive license agreement with City of Hope, a world-renowned cancer research and treatment organization. The agreement grants…

Read More